Peptides News and Research

RSS

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

Researchers show iRGD peptide increases treatment efficacy against cancer

Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

9 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers at the Case Western Reserve University School of Dental Medicine and School of Medicine will look for evidence within the brain for human beta defensin peptide function-proteins important to the peripheral body's natural defense system against infection from the outside environment.

8 Apr 2010

Cephalon acquires biotechnology company, Ception Therapeutics

Cephalon, Inc. announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon.

6 Apr 2010

New report questions the kinetics of T cell receptors

T cell receptors are among the most important molecules in the immune system because of their role in recognizing the antigens that signal such threats as viruses and cancer. The receptors must also distinguish these threats from the body's own cells to avoid triggering an unwanted immune system response.

5 Apr 2010

Some therapies being investigated for Alzheimer's disease may cause cell death: UCSD

Some current therapies being investigated for Alzheimer's disease may cause further neural degeneration and cell death, according to a breakthrough discovery by UC San Diego researchers. By combining three dimensional computer simulations with high resolution atomic force microscopy membrane protein and cell imaging, electrical recording and various cellular assays, UCSD nano-biophysicist Ratnesh Lal and his colleagues investigated the structure and function of truncated peptides, known as nonamyloidgenic peptides, formed by some Alzheimer's drug candidates.

5 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

Study could aid in developing new, effective treatments for prostate cancer

Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.

3 Apr 2010

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

3 Apr 2010

Researchers identify soy peptides that inhibit fat accumulation and reduce inflammation

If you're serious about losing weight, check out recent studies done in Elvira de Mejia's University of Illinois laboratory. Her research provides insight into the way a certain type of soy protein inhibits fat accumulation and reduces inflammation.

2 Apr 2010

Protein vaccines for needle-free immunization through the skin

Most immunizations currently involve an injection in the arm. In the future, vaccination may be accomplished without the unpleasant jab of a needle: a team led by Victor C. Yang at the University of Michigan (USA) has developed a method by which vaccines can pass directly through the skin without a needle. As the researchers report in the journal Angewandte Chemie, merely linking a special short peptide molecule to the vaccine, which can then be administered in the form of a patch, will do the job.

1 Apr 2010

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.

1 Apr 2010

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

The European Hematology Association and the American Society of Hematology have selected Ingmar Bruns, MD, as the seventh recipient of the EHA-ASH Research Exchange Award, which serves to strengthen ties between North American and European scientific communities.

31 Mar 2010

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

By blocking the cellular signaling activity of a protein, a team of neuroscientists at Cold Spring Harbor Laboratory (CSHL) has prevented memory loss in fruit flies caused by brain plaques similar to those thought to cause Alzheimer's disease in humans. The study also resolves a long-standing controversy about the role of this protein, PI3 kinase, which was previously thought to have a protective function against the disease.

30 Mar 2010

Genetically manipulating rats to emulate Alzheimer's disease in humans

Prof. Claudio Cuello at McGill University and his collaborators have genetically manipulated rats that can emulate Alzheimer's disease in humans, enabling research that will include the development of new treatments. Alzheimer's is a devastating brain condition leading to a progressive decline of memory and other brain functions. Although research mice have been developed in the past, rats are more intelligent than other rodents and the behavior of these rats is rich and predictable, which means that for the first time researchers will be able to detect and study the evolution of learning and memory deficits.

30 Mar 2010

Wellness Formulations introduces Dermal Renu Sunshield

Wellness Formulations, LLC, a leader in anti-glycation research and product development, has launched Dermal Renu® Sunshield daily wear SPF 15 sunscreen. This mineral based sunscreen provides broad-spectrum protection from sun damage caused by UVA/UVB rays, while fighting the signs of aging through a unique combination of anti-glycation agents, antioxidants, moisturizing elements, peptides, and botanical extracts.

30 Mar 2010

Kun Run Biotechnology's fiscal 2009 fourth-quarter revenues decrease 19%

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.

30 Mar 2010

Peptides News and Research

Tβ4 therapy for ocular disorders closer to reality

Researchers show iRGD peptide increases treatment efficacy against cancer

Nanotechnology-based vaccine cures mice with type 1 diabetes

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Role of beta defensins in development of chronic inflammatory response in the brain

Cephalon acquires biotechnology company, Ception Therapeutics

New report questions the kinetics of T cell receptors

Some therapies being investigated for Alzheimer's disease may cause cell death: UCSD

Cancer research at Georgia Tech: Report

Study could aid in developing new, effective treatments for prostate cancer

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

Researchers identify soy peptides that inhibit fat accumulation and reduce inflammation

Protein vaccines for needle-free immunization through the skin

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

Genetically manipulating rats to emulate Alzheimer's disease in humans

Wellness Formulations introduces Dermal Renu Sunshield

Kun Run Biotechnology's fiscal 2009 fourth-quarter revenues decrease 19%

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News